These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 12039445)

  • 1. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.
    Stern DM; Yan SD; Yan SF; Schmidt AM
    Ageing Res Rev; 2002 Feb; 1(1):1-15. PubMed ID: 12039445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings.
    Stern D; Yan SD; Yan SF; Schmidt AM
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1615-25. PubMed ID: 12453678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
    Schmidt AM; Yan SD; Wautier JL; Stern D
    Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biology of the receptor for advanced glycation end products and its ligands.
    Schmidt AM; Yan SD; Yan SF; Stern DM
    Biochim Biophys Acta; 2000 Dec; 1498(2-3):99-111. PubMed ID: 11108954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease.
    Schmidt AM; Stern DM
    Front Biosci; 2001 Oct; 6():D1151-60. PubMed ID: 11578972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders.
    Hudson BI; Bucciarelli LG; Wendt T; Sakaguchi T; Lalla E; Qu W; Lu Y; Lee L; Stern DM; Naka Y; Ramasamy R; Yan SD; Yan SF; D'Agati V; Schmidt AM
    Arch Biochem Biophys; 2003 Nov; 419(1):80-8. PubMed ID: 14568011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.
    Yan SF; Ramasamy R; Schmidt AM
    J Mol Med (Berl); 2009 Mar; 87(3):235-47. PubMed ID: 19189073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy.
    Wendt T; Tanji N; Guo J; Hudson BI; Bierhaus A; Ramasamy R; Arnold B; Nawroth PP; Yan SF; D'Agati V; Schmidt AM
    J Am Soc Nephrol; 2003 May; 14(5):1383-95. PubMed ID: 12707408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAGE: a multi-ligand receptor unveiling novel insights in health and disease.
    Alexiou P; Chatzopoulou M; Pegklidou K; Demopoulos VJ
    Curr Med Chem; 2010; 17(21):2232-52. PubMed ID: 20459381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.
    Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM
    Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications.
    Basta G
    Atherosclerosis; 2008 Jan; 196(1):9-21. PubMed ID: 17826783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAGE and its ligands in retinal disease.
    Barile GR; Schmidt AM
    Curr Mol Med; 2007 Dec; 7(8):758-65. PubMed ID: 18331234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding RAGE, the receptor for advanced glycation end products.
    Bierhaus A; Humpert PM; Morcos M; Wendt T; Chavakis T; Arnold B; Stern DM; Nawroth PP
    J Mol Med (Berl); 2005 Nov; 83(11):876-86. PubMed ID: 16133426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.
    Ramasamy R; Yan SF; Schmidt AM
    Vascul Pharmacol; 2012; 57(5-6):160-7. PubMed ID: 22750165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAGE and the pathogenesis of chronic kidney disease.
    D'Agati V; Schmidt AM
    Nat Rev Nephrol; 2010 Jun; 6(6):352-60. PubMed ID: 20421886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation.
    Schmidt AM; Hofmann M; Taguchi A; Yan SD; Stern DM
    Semin Thromb Hemost; 2000; 26(5):485-93. PubMed ID: 11129404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
    Ramasamy R; Yan SF; Schmidt AM
    Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAGE: a novel target for drug intervention in diabetic vascular disease.
    Hudson BI; Schmidt AM
    Pharm Res; 2004 Jul; 21(7):1079-86. PubMed ID: 15290845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications.
    Yan SF; Barile GR; D'Agati V; Du Yan S; Ramasamy R; Schmidt AM
    Curr Diab Rep; 2007 Apr; 7(2):146-53. PubMed ID: 17425919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.